Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Effectiveness of monovalent and pentavalent rotavirus vaccine
Pediatrics, Volume 132, No. 1, Year 2013
Notification
URL copied to clipboard!
Description
OBJECTIVE: Previous US evaluations have not assessed monovalent rotavirus vaccine (RV1, a G1P[8] human rotavirus strain) effectiveness, because of its later introduction (2008). Using case-control methodology, we measured the vaccine effectiveness (VE) of the 2-dose RV1 and 3-dose pentavalent vaccine (RV5) series against rotavirus disease resulting in hospital emergency department or inpatient care. METHODS: Children were eligible for enrollment if they presented to 1 of 5 hospitals (3 in Georgia, 2 in Connecticut) with diarrhea of ≤10 days' duration during January through June 2010 or 2011, and were born after RV1 introduction. Stools were collected; immunization records were obtained from providers and state electronic immunization information system (IIS). Case-subjects (children testing rotavirus antigenpositive) were compared with 2 control groups: children testing rotavirus negative and children selected from IIS. RESULTS: Overall, 165 rotavirus-case subjects and 428 rotavirus-negative controls were enrolled. Using the rotavirus-negative controls, RV1 VE was 91% (95% confidence interval [CI] 80 to 95) and RV5 VE was 92% (CI 75 to 97) among children aged ≥8 months. The RV1 VE against G2P[4] disease was high (94%, CI 78 to 98), as was that against G1P[8] disease (89%, CI 70 to 96). RV1 effectiveness was sustained among children aged 12 through 23 months (VE 91%; CI 75 to 96). VE point estimates using IIS controls were similar to those using rotavirusnegative controls. CONCLUSIONS: RV1 and RV5 were both highly effective against severe rotavirus disease. RV1 conferred sustained protection during the first 2 years of life and demonstrated high effectiveness against G2P[4] (heterotypic) disease. Pediatrics 2013;132:e25-e33. Copyright © 2013 by the American Academy of Pediatrics.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC4074617/bin/supp_132_1_e25__index.html
https://efashare.b-cdn.net/share/pmc/articles/PMC4074617/bin/peds.2012-3804_peds.2012-3804SupplementaryData.pdf
Authors & Co-Authors
Immergluck, Lilly Cheng
United States, Atlanta
Children's Healthcare of Atlanta
United States, Atlanta
Morehouse School of Medicine
Quaye, Osbourne
United States, Atlanta
Centers for Disease Control and Prevention
Mijatovic-Rustempasic, Slavica
United States, Atlanta
Centers for Disease Control and Prevention
Gautam, Rashi
United States, Atlanta
Centers for Disease Control and Prevention
Bowen, Michael D.
United States, Atlanta
Centers for Disease Control and Prevention
Moore, Jessica
United States, Atlanta
Centers for Disease Control and Prevention
Tate, Jacqueline E.
United States, Atlanta
Centers for Disease Control and Prevention
Parashar, Umesh D.
United States, Atlanta
Centers for Disease Control and Prevention
Statistics
Citations: 101
Authors: 8
Affiliations: 6
Identifiers
Doi:
10.1542/peds.2012-3804
ISSN:
10984275
Research Areas
Health System And Policy
Maternal And Child Health
Study Design
Case-Control Study